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Abstract,  Von Willebrand factor (vWF) is a constitu- 
tive and specific component of endothelial cell (EC) 
matrix.  In this paper we show that,  in vitro, vWF can 
induce EC adhesion and promote organization  of 
microfilaments and adhesion plaques.  In contrast,  hu- 
man vascular smooth muscle cells and MG63 os- 
teosarcoma cells did not adhere and  spread on vWE 
Using antibodies to the/3 chains of fibronectin (~) 
and vitronectin (~3) receptors it was found that ECs 
adherent to vWF show clustering of both receptors. 
The/3,  receptor antibodies are arranged  along stress 
fibers at sites of extraceUular matrix contact while the 
/33 receptor antibodies were sharply confined at adhe- 
sion plaques.  ECs release and organize endogenous 
fibronectin early during adhesion to vWE  Upon block- 
ing protein synthesis and secretion,  ECs can equally 
adhere and spread on vWF but, while the ~3 receptors 
are regularly organized,  the ~,  receptors remain 
diffuse. This suggests that the organization of the/31 
receptors depend on the release of fibronectin and/or 
other matrix proteins operated by the same cell.  Anti- 
bodies to the ~3 receptors fully block EC adhesion to 
vWF and detach ECs seeded on this  substratum.  In 
contrast,  antibodies to the ~  receptors are poorly ac- 
tive. Overall these results fit with an accessory role of 
~  receptors and indicate a leading role for the ~3 
receptors in EC interaction with vWF.  To identify the 
EC binding domain on vWF we used monoclonal anti- 
bodies produced against a peptide representing  the 
residues Glu1737-Ser175° of the mature vWF and thought 
to be important  in mediating its binding to the platelet 
receptor glycoprotein IIb-IIIa. We found that the anti- 
body that recognizes the residues  1,744-1,746,  contain- 
ing the Arg-Gly-Asp sequence, completely inhibit EC 
adhesion to vWF whereas a  second antibody recogniz- 
ing the adjacent residues  1,740-1,742  (Arg-Gly- 
Asp-free) is inactive.  Both antibodies do not interfere 
with EC adhesion to vitronectin.  This defines the mo- 
lecular domain on vWF that is specifically recognized 
by ECs and reaffirms the direct role of the Arg-Gly- 
Asp sequence as the integrin receptor recognition site 
also in the vWF molecule. 
V 
or~ Willebrand  factor (vWF)' is a  large  multimeric 
plasma protein which plays a key role in promoting 
platelet adhesion  to damaged vessel walls (Girma et 
al.,  1987; Baumgartner  et al.,  1980;  Sakariassen  et al., 
1979).  Plasma vWF binds to subendothelial  structures  and 
this is followed by the interaction with the platelet membrane 
glycoprotein  Gplb  which  mediates  platelet  adhesion  and 
spreading  on the surface (Sakariassen  et al.,  1986; Weiss et 
al., 1986). Under some circumstances,  such as after thrum- 
bin activation,  vWF also binds to the platelet membrane gly- 
coprotein complex GplIb-IIIa and promotes platelet aggre- 
gation  (Fujimoto et al.,  1982; Ruggeri et al.,  1982,  1983). 
1. Abbreviations  used in this paper: EC, human umbilical vein endothelial 
cell; fg, fibrinogen; fn, fibronectin; F-PHD, fluorescein-labeled phalloidin; 
M199,  medium  199;  RGD,  L-arginyl-glycyl-L-aspartate;  R-PHD,  rhoda- 
mine-labeled phalloidin; vn, vitronectin; vWF, von Willebrand factor. 
The structural  characteristics  of the human platelet vWF 
receptors Gplb and GplIb-IIIa as well as their specific bind- 
ing domains on the vWF molecule have been defined (Girma 
et al.,  1987; Nurden,  1987).  These two receptors are not 
structurally  related  and recognize  different domains on the 
vWF molecule.  The GplIb-IIIa complex of platelets belongs 
to a newly discovered superfamily  of cell adhesion receptors 
named "integrins" (reviewed in Hynes, 1987; Ruoslahti  and 
Pierschbacher,  1987). These molecules have several struc- 
tural and functional  homologies and recognize a number of 
extracellular matrix components via a common Arg-Gly-Asp 
(RGD) sequence (Ruoslahti and Pierschbacher,  1986). Since 
vWF contains the latter sequence (Titani et al., 1986), RGD- 
containing  peptides have been tested on platelets  and found 
to  inhibit  its  binding  to  Gpllb-ffla  (Plow et al.,  1985b; 
Haverstick et al., 1985). In addition,  studies with proteolytic 
fragments  using binding assays and specific mABs directed 
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recognized by Gplb and GplIb-IIIa in sites located between 
residues  449-728  (RGD  -)  and  1,366-2,050  (RGD  +), 
respectively  (Girma et  al.,  1986, 1987; Fujimura et  al., 
1986). 
While the important role of vWF factor in platelet adhe- 
sion and thrombus formation is fully recognized (Stel et al., 
1985; Turitto et al.,  1985),  very little is known on the role 
of this protein in promoting adhesion of other cell types. In 
fact, beside being a plasma protein, vWF is also a constitu- 
tive  component  of the  subendothelial  matrix  (Giddings, 
1986).  Endothelial cells (ECs) and megakaryocytes are the 
only cells that synthesize vWF (Jaffe et al.,  1973;  Wagner 
and Marden, 1983). ECs can both release vWF in the blood 
stream and organize it in close association with other matrix 
proteins within the subendothelial basement lamina (Gid- 
dings, 1986). Therefore, since vWF is an important and spe- 
cific component of the endothelial cell matrix, it is relevant 
to understand which is its role in promoting endothelial cell 
adhesion and to define the structural features of this inter- 
action. 
ECs possess at least two components of the "integrin" su- 
perfamily immunologically and structurally comparable to 
the fibronectin (fn) and vitronectin (vn) receptors of fibro- 
blasts and tumor cells (Fitzgerald et al.,  1985; Plow et al., 
1985a;  Suzuki et al.,  1987; Cheresh,  1987; Dejana et al., 
1988b,c;  Conforti et al., 1989). In previous papers (Dejana 
et al., 1988b,c) we have shown that these receptors are local- 
ized in adhesion structures and that their distribution and lo- 
calization is controlled by their specific ligands. In the pres- 
ent study we report that vWF promotes EC adhesion and 
cytoskeletal organization. This involves a peculiar mode of 
distribution of putative fn and vn receptors in adhesion struc- 
tures. We show that, in vitro, both receptors are organized 
in focal contacts but that only a putative vn receptor plays a 
relevant role in maintaining EC adhesion and spreading on 
vWF. In addition, we demonstrate that RGD peptides and 
antibodies raised against the vWF  sequence from Glu 1.737 
to Ser ~,75° including the residues Arg-Gly-Asp,  specifically 
block EC adhesion to vWE These data provide evidence that 
vWF acts as other matrix proteins in promoting EC adhesion 
and cytoskeletal organization. This interaction appears to be 
mediated by a  recognition mechanism which has features 
similar to those occurring in platelets via GplIb-IIIa. 
Materials and Methods 
Cell Cultures 
ECs were isolated from human umbilical cords and cultured as described 
previously (Barbieri et al.,  1981). The cells were grown to confluency in 
plastic fasks (Falcon Labware, Oxnard, CA) in medium 199 (M199)  sup- 
plemented with 20% FCS. Cell cultures were incubated at 37°C in a water- 
saturated atmosphere of 95% air-5% CO2 and fed three times a week. ECs 
were routinely characterized by indirect immunofluoreseence using rabbit 
anti-human factor VIII antigen (Behringwerke AG, Marburg, FRG). ECs 
were used between the first and the fifth passage. 
The human osteosarcoma cell line MG63 (American Type Culture CoL- 
lection, Rockville,  MD) and human femoral artery smooth muscle cells 
(kindly donated by Dr. G. Gabbiani, University of Geneva School of Medi- 
cine, Geneva, Switzerland) were grown in DME supplemented with 10% 
FCS and cultured as described for ECs. 
All culture reagents were from Gibco Laboratories (Paisley,  Scotland). 
Source of vn and vWF 
Human plasma vn was a kind gift of Dr.  K.  T.  Preissner (Max Planck- 
Gesellschafl, Justus Liebig-Universit~t, Giessen, FRG) and was purified 
from human plasma as previously described (Preissner et al.,  1985). 
Human plasma vWF was purified following procedures previously de- 
scribed in detail (De Marco and Shapiro, 1981). All the vWF preparations 
were tested by SDS electrophoresis and show no evidence of contamination 
by a protein of the expected molecular mass of vn. Human plasma fn was 
purified from freshly drawn citrated blood plasma by affinity chromatogra- 
phy on gelatin Sepharose (Engvall and Ruoslahti,  1977).  Human plasma 
fibrinogen (fg)  was purified as described (Kekwick et al.,  1955). 
Peptides 
The synthetic hexapeptides Gly-Arg-Gly-Asp-Ser-Pro (GRGDSP) and Gly- 
Arg-Gly-Glu-Ser-Pro (GRGESP) were synthesized by Dr. P. Neri (Centro 
di Ricerca Interdipartimentale per le Scienze Mediche Avanzate, University 
of Siena, Siena, Italy) using an automated peptide synthesizer (model n. 
430; Applied Biosystems Inc., Foster City, CA) equipped with the chemical 
supplies provided by the manufacturer as described (Conforti et al., 1989). 
Preparation and Coating of  Glass Coverslips 
Glass coverslips (10 mm in diameter) were cleaned by sonication for 10 rain, 
then immersed in ethanol-ether (1:1, [vol/vol])  for 2 h and dried before plac- 
ing in multiwell tissue culture plates (Falcon Labware). The coverslips were 
coated either with 0.3 ml vn (10/.tg/ml), fn (10 ~g/ml), or vWF (30 #g/ml) 
in Ca2+-Mg  2+ PBS, pH 7.4,  for 2 h at 37°C. After extensive rinsing, resid- 
ual protein binding sites on coverslips were saturated by further incubation 
(30 min, 37°C) in 1% BSA containing divalent ions. Vn, fn, and vWF had 
a diffuse and uniform pattern of distribution on the glass as assessed by im- 
munofluorescence staining with specific antibodies to either protein (see 
below). 
Antibodies 
In this study we have used a set of integrin antibodies recognizing either 
the/31  or the/33 subunits corresponding to the/3 chains of the fn and vn 
receptor, respectively./31  antibodies were (a) a mouse mAB, clone A-1A5 
(Hemler et al., 1987) obtained from Dr.  M. Hemler (Dana Farber Cancer 
Institute, Boston, MA); (b) a human placenta fn receptor goat antiserum 
prepared in our laboratories and characterized elsewhere (Conforti et al., 
1989).  /33  antibodies were (a)  a  mouse mAB  (clone VIPI-2) to human 
platelet GplIIa  obtained  from  Dr.  W.  Knapp (Institute of Immunology, 
University of Vienna, Vienna, Austria); (b) a GpIIIa mAB (7E3) kindly 
provided by Dr.  B. Coller (State University of New York,  Stony  Brook, 
NY); (c) rabbit affinity-purified human vn receptor antibodies (Pytela et al., 
1985) obtained through the courtesy of Dr. R. Pytela, Basel Institute for Im- 
munology, Basel, Switzerland; (d) a GpIIIa rabbit antiserum prepared in 
our laboratories and previously described (Dejana et al.,  1988b).  Preim- 
mune goat and rabbit sera and a  human platelet GpIIb-IIIa mAB (10E5, 
kindly donated by Dr. B. Coller), which does not recognize endothelial cells 
(Charo et al.,  1987),  were used as negative controls. 
Monoclonal antibodies against the synthetic peptide corresponding to the 
sequence Glu 1737 to Ser 175° of the mature vWF were prepared essentially 
as described previously (Berliner et al., 1988). Monoclonal antibodies were 
produced by immunizing BALB/c mice with intraperitoneal injections of  the 
peptide coupled to keyhole limpet hemocyanin (Berliner et al., 1988).  Cul- 
ture supernatants from hydridomas were tested for reactivity against vWF 
using an ELISA. Monoclonal IgGs were then produced in mouse ascites 
fluid. Purified lgGs were obtained by affinity chromatography on Protein 
A-Sepharose (Sigma Chemical Co., St. Louis, MO). The antibodies were 
purified by passing them through a column of native peptide linked to cyano- 
gen bromide-activated Sepharose 4B (Pharmacia Fine Chemicals, Uppsala, 
Sweden). The approach used for defining the amino acid residues involved 
in antibody binding was that of measuring the ability of the native peptide 
and of analogous peptides containing single amino acid substitutions to 
block binding of the antibodies to native vWF, as previously described in 
detail (Berliner et al.,  1988). 
Goat anti-human fn was a gift of Dr. G. Tarone (University of Torino, 
Torino,  Italy).  Rabbit anti-human plasma vn was donated by Dr.  K. T. 
Preissner. Rabbit anti-vWF factor antiserum was purchased from Behring- 
werke AG. A mouse mAB (1ST-9) to the ED domain specifically expressed 
by cell-assembled fn and not by plasma fn (Borsi et al., 1987; Carnemolla 
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Zardi  (lstituto Scientifico per Io Studio e  la Cura dei Tumori,  Genova, 
Italy).  Rabbit anti-human plasma fibrinogen was prepared as described 
(Marguerie et al.,  1982). 
The localization of vinculin was assayed with a mouse mAB to chicken 
gizzard vinculin and cross-reacting with the mammalian form (clone VIN- 
11-5, code n. 6501;  Bio-Yeda Rehovot, Israel). 
Adhesion and Spreading Assays 
ECs were grown in 25-cm  2 flasks ("~1  x  106 cells/flask). The cells were 
then washed with 5  ml PBS and detached by brief (20-s) exposure to a 
prewarmed 0.25% trypsin-0.5 mM EDTA solution in PBS. As soon as cells 
began rounding up, trypsin-EDTA solution was discarded and 5 ml M199 
supplemented with 20% serum to neutralize trypsin were added. The cells 
were then completely detached by gentle shaking within 5 rain. 
For immunofluorescence experiments, detached cells were quickly spun 
at  1,200  g  and  resuspended in  serum-free M199  at  a  concentration of 
150,000-200,000  cells/ml and 0.3 ml of cell suspension was seeded on each 
coated coverslip. After 2 or 4 h incubation at 37°C, the wells were washed 
three times with  1 ml PBS containing Ca2+-Mg  2+ and coverslip-attached 
cells were fixed in 3% formaldehyde (from paraformaldehyde) in PBS, pH 
7.6, containing 2% sucrose for 5 min at room temperature. After rinsing in 
PBS, cells were permeabilized to antibodies by soaking coverslips for 3-5 
min at 0°C in HEPES-Triton X-100 buffer (20 mM HEPES, pH 7.4,  300 
mM sucrose, 50 mM NaCI, 3 mM MgCI2,  and 0.5% Triton X-100).  This 
procedure of fixation and permeabilization has been successfully used for 
other studies of EC cytoskeleton and adhesion (e.g., Dejana et al.,  1987, 
1988b,c). 
To  quantify cell adhesion,  in  separate experiments, ECs were  resus- 
pended in serum-free M199 and incubated on plastic microtiter wells pre- 
coated with the different substrata (20,000  cells/well in 100 #l). After 2 or 
4 h incubation at 37°C, unbound cells were removed by washing twice with 
PBS containing Ca2+-Mg  2+ and adherent cells were fixed and stained with 
May-Griinwald Giemsa staining mixture. To quantify adhesion the light ab- 
sorbance of stained cells on the microtiter well surface was measured by an 
automated photometer (Titertek, Elfab Oy,  Finland). 
The direct involvement of 83 receptors or of a series of matrix proteins 
(fn, vn, vWE and fg) in supporting the adhesion of ECs was tested by adding 
the corresponding antibodies to cell suspensions 30 rain before seeding on 
different substrata. The antibodies were then kept during the adhesion assay. 
In some experiments, ECs were plated with or without 5 #g/ml emetine 
(Sigma Chemical Co.) or 0.7 #g/ml monensin (Sigma Chemical Co.) to in- 
hibit protein synthesis and secretion, respectively (Uchida et al.,  1979; 
Dejana et al.,  1988a).  Cells were treated with the drugs for  1 h  before 
detachment and kept in the presence of the drugs during detachment and 
for the whole duration of the adhesion assay. 
The ability of/3~ and 133 antibodies to induce detachment and cytoskele- 
tal changes of ECs after adhesion was tested by adding the antibodies to 
confluent ECs. For these experiments ECs were seeded on vWF, vn, or fn 
coated coverslips as described above and let to adhere and spread for 4 h. 
After two washes with 1 ml PBS the/31 receptor goat antiserum (1:35 dilu- 
tion),  the GpIIb-IIIa mAB 7E3  (1:20  dilution),  the corresponding goat 
preimmune sera (l: 10 dilution), or the mAB 10E5 (1:10 dilution) were added 
in serum-free M199. After 4 h incubation the adherent ECs were fixed and 
stained as described below. 
Fluorescence Studies 
To show F-actin in the process of cell spreading and microfilament organiza- 
tion, fixed and permeabilized cells were stained with 2/~g/ml rhodamine- 
labeled phalloidin (R-PHD; a kind gift of Dr. T. Wieland, Max Planck Insti- 
tute for Experimental Medicine, Heidelberg, FRG) for 30 min at 37°C. 
Indirect immunofluorescence experiments were performed as reported 
(Dejana et al.,  1987, 1988b,c).  Briefly,  the primary antibody was layered 
on fixed and permeabilized cells and incubated in a humid chamber for 30 
min. After rinsing in PBS-0.2 % BSA, coverslips were incubated in the ap- 
propriate  rhodamine-tagged  secondary  antibody  (Dakopatts,  Glostrup, 
Denmark) for 30 min at 37°C in the presence of 2 /~g/ml of fluorescein- 
labeled phalloidin (F-PHD, a gift of Dr. T. Wieland). Coverslips were then 
mounted in 50% glyceroI-PBS. 
Observations were carried out  in  a  Zeiss Axiophot photomicroscope 
equipped for epifluorescence and interference reflection microscopy. Fluo- 
rescence images were recorded on Kodak T-Max 400 films exposed at 1,000 
ISO and developed in Kodak T-Max developer for  10 min at 20°C. 
Results 
EC Adhesion to vWF 
ECs seeded on vWF-coated coverslips in the absence of se- 
rum, spread and organized microfilaments in bundles of the 
stress  fiber type (Fig.  1 A).  Immunofluorescence staining 
using 133 antibodies gave a peculiar pattern of oval or arrow- 
head-shaped spots usually sharply located at stress fiber end- 
ings (Fig.  1 B).  Also, they corresponded to dark spots in 
interference refection microscopy indicating that the mole- 
cules  cross-reacting  with  /33  antibodies  were  colocalized 
with adhesion plaques (not shown). ECs, upon adhesion on 
vWE were immunostained also with/3~  antibodies (Fig.  1 
D). A rather typical localization was found along some stress 
fibers (compare Fig.  1,  C with D) with almost no reaction 
at their termini indicating that little if any codistribution of 
the two receptors occurred. Identical patterns were respec- 
tively recorded with any/3j or/33 antibody. 
The pattern of EC adhesion, cytoskeletal organization and 
distribution  of /33  antibodies  on  a  vWF  substratum  was 
comparable to that obtained on vn (Fig.  1 E and F). How- 
ever, upon seeding on vn, only/33 antibodies were distrib- 
uted in focal contacts while/3~  antibodies remained diffuse 
on the surface (Fig.  1,  G and H). 
The time course of EC adhesion on vWF vs. vn appeared 
to be slightly different. While ECs  seeded on vn reached 
maximal adhesion and spreading within 2 h,  ECs on vWF 
achieved full spreading only after 3.5-4.0  h  (not shown). 
Therefore, in the experiments described below, ECs were let 
to adhere on fn or vn for 2 h and on vWF for 4 h to achieve 
full and homogeneous spreading. 
The organization of vinculin, taken as a probe of the or- 
ganizing microfilament-membrane interaction complex, was 
also observed in ECs adhering on vWF (Fig.  1, I and L). It 
was found that, on vWE vinculin was localized at adhesion 
plaques and also,  in a  lesser amount,  along the length of 
some stress fibers (Fig. 1, I and L, e.g., at small arrows) pre- 
sumably matching the described localization of/3, and/33 
receptors. On vn, however, vinculin was found only at 133- 
containing adhesion plaques (not shown; see also Dejana et 
al.,  1988b). 
Specificity of  EC Interaction with vWF 
To investigate the specificity of EC adhesion to vWF, specific 
antibodies to fn, vn, fg, and vWF were incubated with vWF- 
coated coverslips during EC adhesion and left in the culture 
medium for the duration of the experiments. As reported in 
Table I, vWF antibodies blocked EC adhesion and spreading 
to vWF but no effect was observed using antibodies to other 
matrix proteins. However, all of them were active in inhibit- 
ing EC adhesion to their specific antigens. 
Role of  Protein Synthesis and Secretion on EC 
Adhesion to vWF 
To investigate the role of synthesis and secretion of proteins 
in the process of adhesion to vWE ECs were treated with 5 
/~g/ml  emetine to block protein  synthesis  (Dejana  et al., 
1988a) or with 0.7/zg/ml monensin to prevent glycoprotein 
secretion  (Uchida  et  al.,  1979).  As  reported  in  Fig.  2, 
monensin treatment did not change EC adhesion, spreading 
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to Different Substrata 
Substrata (percent of inhibition) 
Antisera  fn  vn  vWF  fg 
anti-fn  87  +  6  0.6  +  0.1  0.1  +  0.2  0.3  +  0.01 
anti-vn  0,1  +  0.02  76.0  _+  8.0  8.0  +  0.5  0.9  +  0.01 
anti-vWF  0,3  _  0.08  0.1  -k-  0.2  78.0  +  7.0  12.0  -I-  1.0 
anti-fg  3.0  ___  0.4  0.6  ±  0.03  0.5  ±  0.1  91.0  +  8.0 
ECs were resuspended in serum-free M 199 and incubated on plastic microtiter 
wells precoated with the different substrata.  Antibodies to fn (1:20 dilution), 
vn (at 1:50), vWF (1:20), and fg (I :20) were added to the cells 30 rain before 
seeding at 37°C. The antibodies were kept in the medium during the adhesion 
assay.  After 2 h (on fn or vn) or 4 h (on fg or vWF) incubation at 37°C, un- 
bound cells were removed by washing twice with PBS containing Ca  2+ -Mg  2+ 
and adherent cells were fixed and stained with May-Griinwald Giemsa staining 
mixture.  To quantify  adhesion  the  light  absorbance  of stained  cells  on  the 
microtiter  well surface was measured.  The values,  expressed as a percent of 
inhibition of attachment compared to the total number of cells adherent in the 
absence of antibodies,  are  means _+  SEM of three  separate experiments per- 
formed on three  separate cell cultures. 
and/33 receptor clustering on vWF (Fig. 2, A and B) but in- 
hibited the appearance of the slender clusters of ~,  recep- 
tors along stress fibers (Fig.  2,  C and D). 
Next,  we tested the secretion and organization of the fn 
produced by ECs using a mouse mAB specifically recogniz- 
ing an epitope on the ED domain of cellular fn (Borsi et al., 
1987; Carnemolla et al., 1987). Such an antibody (IST-9) did 
not recognize plasma fn but intensely reacted with the fn pro- 
duced by ECs.  When untreated cells were spread on vWF, 
fn  was organized  in  typical fibrils  underneath  the  ventral 
membrane that were easily detected when the cells had been 
removed by a stream of buffer (Fig. 2, E and F).  Upon ex- 
posure to monensin, the secretion of fn and its organization 
on the  substratum was totally  inhibited  and,  instead,  ECs 
were loaded with fn-containing vesicles (Fig. 2, G and H). 
Virtually identical results were obtained by treating ECs 
with emetine (not shown). 
Involvement of  l3~Receptor on EC Adhesion to vWF 
The exposure of confluent ECs seeded either on vWF or vn 
to/33 antibodies for 4 h produced an extensive loss of inter- 
cellular  contacts  and  disruption  of the  continuity  of the 
monolayer (Fig.  3, A and B).  In contrast,  no effect of the 
same antibody was observed on ECs seeded on fn (Fig. 3 C). 
Vice versa, addition of/3~ antibodies to confluent ECs dra- 
matically disrupted the continuity of monolayers only when 
cells were seeded on fn (Fig.  3 F) whereas little effect was 
obtained on vn (Fig.  3 E) or on vWF (Fig.  3 D). 
In  some experiments ~3 antibodies  were  added  to  ECs 
during  the  adhesion  assay.  These antibodies  inhibited  EC 
adhesion to vWF and  vn (Fig.  3,  G  and H) but not to fn 
(Fig.  3 I). 
No effect on cell detachment or inhibition of cell adhesion 
was observed either with goat preimmune serum (1:10 dilu- 
tion) or mAB  10E5 (1:10 dilution) (data not shown). 
Role of the RGD Sequence on EC Adhesion to vWF 
The  Gly-Arg-Gly-Asp-Ser-Pro (GRGDSP)  peptide  corre- 
sponding to the cell binding sequence of fn was tested on EC 
adhesion. As reported in Fig. 4 A, GRGDSP produced a con- 
centration  dependent  inhibition  of EC  adhesion  to  vWE 
Adhesion was blocked at 100 #g/ml of the peptide. As ex- 
pected, adhesion to vn was equally or slightly less inhibited. 
No inhibition of EC adhesion to both substrata was observed 
when  the  peptide  was  replaced by its analogue  GRGESP 
where the Asp residue was replaced by Glu. 
Two mouse mABs raised to a synthetic peptide of human 
vWF between residues 1,737 and 1,750 of mature vWF were 
tested on EC adhesion. As reported in Fig. 4 B, the 152B-20 
antibody directed to residues 1,744-1,747  including the RGD 
sequence was able to block EC adhesion to vWF (o) but was 
inactive on vn (zx). Conversely, 152B-18 directed to the adja- 
cent RGD-free sequence 1740-1742 did not produce any inhi- 
bition on vWF (o) and vn (not shown). 
Spreading and Organization of Microfilamentous 
Structures of Other Cell ~pes Seeded on vWF 
To investigate whether EC interaction with vWF was a spe- 
cific phenomenon or could also occur with other cell types 
lacking vWF in their basement lamina, we assayed adhesion 
and spreading of human osteosarcoma cells (MG63) and of 
human  arterial  smooth  muscle  cells  on  vWF-coated  sub- 
strata.  MG63 or human smooth muscle cells adhered and 
spread on fn (Fig. 5, A and C, respectively) but did not do 
so on vWF (Fig. 5, B and D). The same cell types adhered 
and spread also when seeded on vn (not shown). 
Discussion 
In this article we describe several new observations on the 
mechanism of EC  interaction  with  vWF.  First,  we report 
here that vWF not only promotes EC adhesion as previously 
reported (Cheresh,  1987; Charo et al.,  1987) but that it also 
acts as a genuine matrix protein in promoting the organiza- 
tion of microfilaments and adhesion plaques via a transmem- 
brane mechanism. Qualitatively the pattern of spreading and 
microfilament organization and the number and extent of fo- 
cal contacts is closely comparable to that obtained on vn or 
fn  substrata  (Dejana  et  al.,  1988b).  We  have previously 
shown that when ECs are seeded either on vn or fn substrata, 
clustering of their specific integrin receptors and the organi- 
zation thereafter of focal contacts occur only on cells sitting 
on the specific ligand and not on the opposite one (Dejana 
et al.,  1988b). In this study however, ECs adherent to vWF 
Figure L Distribution of B3 receptors (B and F),/3~  receptors (D and H), vinculin (L), and F-actin (A, C, E, G, and I) in human ECs 
cultured for 4 h on coverslips coated with vWF (A-D, L and L) or with vn (E-H). The cells were immunofluorescently stained with rabbit 
/33 antibodies (B and F) or mAbs to fll (D and H) and vinculin (L) and costained with F-PHD. On vWF, there is a well-defined localization 
of Ha receptors (B) at stress fiber endings (A) in the form of discrete oval or needle-eye spots (arrowheads) while the/3~ receptors are in 
long linear clusters (D) matching stress fibers and no sign of enrichment  at their endings (C). On vn, there is no patterned localization 
of the/3~ receptors (H), while the/~3 receptors are localized in spots (F) or needle eyes (F, arrowhead) corresponding  to the termini of 
stress fibers (E). In ECs spread on vWF vinculin is both at adhesion plaques and, weakly, along stress fibers (L and L arrows). Bar, 5/~m. 
Dejana et al.  Endothelial  Cells and von  Willebrand Factor  371 Figure 2. ECs spread on vWF in the presence (A-D, G, and H) or in the absence (E and F) of 0.7 ttg/ml monensin and showing the distribu- 
tion of/~3 receptors (B),/31 receptors (D), cell-assembled fn (F and H), and the corresponding F-actin distribution (A, C, E, and G). Upon 
monensin treatment the/33 receptors are mostly clustered in peripheral spots at stress fiber endings (A and B) and enriched in the Golgi 
complex area indicating some inhibition of surface exposure. The/~t  receptors are not clustered in linear arrays (compare D with Fig. 
1 D) but are diffuse in the membrane and enriched in the Golgi area. Cellular fn, specifically immunostained with the mAil IST-9 (see 
text), appears organized in the matrix (e.g., at asterisk) and underneath the ventral membrane in control ECs (E and F) but is retained 
in intracellular vesicles (G and H) upon monensin treatment with no evidence of extracellular organization. Bar, 5 #m. 
show clustering of both/33 and HI receptors. The localiza- 
tion pattern of the receptors appears to be very different and 
they do not seem to codistribute in the same structures. The 
~3  receptor is  sharply  localized at  stress  fiber endings  in 
oval spots occasionally with a needle-eye appearance while 
the/3, receptor is mostly arranged along stress fibers and to 
a much lesser extent at their termini. This corresponds also 
to a different distribution of vinculin. Overall, these findings 
indicate that vWF can induce the organization of/33 and ~ 
integrins. 
This result could be explained by speculating that the large 
vWF molecule can be recognized by different integrin recep- 
tors.  However, upon blocking protein synthesis and secre- 
tion, ECs can equally adhere and spread on vWF but only 
the/~3 receptor is organized in adhesion structures while the 
/3~  receptor  is  diffusely  distributed.  These  data  indicate 
that, per se, EC adhesion to vWF is independent of de novo 
synthesis or release of endogenous proteins but the cluster- 
ing of/3, appears to depend on newly released molecules. 
Singer et al. (1988) have suggested that fn receptor distribu- 
tion along stress fibers might be controlled by extracellular 
matrix fiber deposition.  Indeed we show that ECs release 
and organize a  network of fn fibers early when seeded on 
vWF  and  this  can  in  turn  account  for  the  peculiar  /3, 
clustering and the eventual strengthening of EC adhesion. 
However the extent of fn  fibrils appears  smaller than the 
fibrillar organization of the/3~ receptor. One possible expla- 
nation is that, together with fn, EC release other matrix pro- 
teins (as collagen and laminin). These proteins can be recog- 
nized by other members of the "integrin superfamily" which 
share the same/3,  chain with the fn receptor (Wayner and 
Carter,  1987).  This might justify a  more intense staining 
with our antibodies directed to the ~,  chain.  Alternatively 
B,  receptors and  fn might independently be assembled  in 
fibrils by cytoskeletal structures as actin microfilaments. 
The data presented here fits with an accessory role of/3~ 
receptors and points to a  leading role for a/33 receptor in 
EC adhesion to vWF as also confirmed by the fact that/33 
and not/3, receptor antibodies detach ECs seeded on vWE 
Our results are in agreement and extend the data obtained by 
other authors (Cheresh,  1987; Charo et al.,  1987) showing 
that antibodies to GplIb-IIIa and to glycoproteins related to 
the vn receptor could inhibit EC adhesion to vWF. 
A second point is that vWF appears to be an adhesion mol- 
ecule for ECs, but not for human MG63 osteosarcoma cells 
or human  smooth  muscle cells which do not adhere and 
spread on this substratum. This is most intriguing consider- 
ing that the ~3 receptor complex identified in ECs (Fitzger- 
ald et al.,  1985; Plow et al.,  1985; Cheresh,  1987) has the 
same biochemical and immunological characteristics as the 
vn receptor isolated from MG63  cells or human placenta 
(Pytela et al.,  1985). In addition, ECs express mRNAs for 
the MG63 vn receptor (Suzuki et al., 1987). We cannot offer 
a direct explanation for this discrepancy. Minor differences 
in the amino acid sequence of the receptor chains, or in the 
ability of the cells to modulate receptor specificity might be 
considered. 
A third major point of this study deals with the identifica- 
tion of the EC binding domain on the vWF molecule. In this 
study we used two mABs raised against a synthetic peptide 
corresponding to residues  1,737-1,750 of mature vWF.  The 
mAB  152B-20 to this  peptide directed to residues  1,744- 
The Journal of Cell Biology,  Volume  109, 1989  372 Figure 3. The effects of/33 (A-C and G-I) and ~l (D-F) receptor  antibodies on ECs either spread on vWF (A and D), vn (B and E), and 
fn (C and F) or during adhesion on vWF (G), vn (H), and fn (I)./~3  receptor  mAB 7E3 (1:20 dilution) induces the detachment of ECs 
plated on vWF (A) and vn (B) but not on fn (C) while/31 receptor  goat serum (1:35 dilution) detaches  ECs on fn (F) but is only weakly 
active on vWF (D) and vn (E). The process  of adhesion and spreading  is totally inhibited by mAB 7E3 (dilution 1:20) on vWF (G) and 
vn (H) but is not affected on fn (I). All the cells were stained with R-PHD for F-actin. Bar, 20 #m. 
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Figure 4.  Concentration-dependent inhibition of EC adhesion by 
synthetic  peptides  (A) and mABs to vWF (B).  ECs were  resus- 
pended in serum-free M199 and incubated on plastic microtiter 
wells precoated with vWF (30/xg/ml) or vn (7 #g/ml). (A) Increas- 
ing concentrations of the peptides  (Gly-Arg-Gly-Asp-Ser-Pro,  e, 
A; and Gly-Arg-Gly-Glu-Ser-Pro,  (o, A) were added  to the cells 
just before seeding on vWF (e, o) or vn (A, I,). (B) mABs to vWF 
152B-20 (e, zx) and 152B-18 (o) were incubated with the cells in 
suspension for 30 min at 37°C, ECs were then seeded on vWF (e, 
o) or on vn (zx). Peptides and antibodies were kept in solution dur- 
ing the adhesion assay. After 2 h (on vn) or 4 h (on vWF) incubation 
at 37°C, unbound cells were removed by washing twice with PBS 
and adherent cells were  fixed  and  stained with  May-Griinwald 
Giemsa staining  mixture. To quantify adhesion the light absorbance 
of stained cells on the microtiter well surface was measured by an 
automated  photometer. 
Dejana et al. Endothelial Cells and von  Willebrand Factor  373 Figure 5. The process of spreading and cytoskeletal organization of the human osteosarcoma cell line MG63 (A and B) and human femoral 
artery smooth muscle cells (C and D) occurs on fn (,4 and C) but does not occur on vWF (B and D). All the cells were fixed and stained 
with R-PHD for F-actin 4 h after seeding. Bar, 10 #m. 
1,747, including the RGD sequence, fully inhibits  EC adhe- 
sion to this protein. Conversely, the mAB 152B-18,  recogniz- 
ing the  adjacent  residues  1,740-1,742,  is inactive on ECs. 
These data indicate that the vWF molecular domain specif- 
ically recognized by ECs is closely related or identical to that 
recognized by platelet Gpllb-RIa. 
The presence of Gplb on ECs is still a matter of debate. 
Ash et al. (1988) showed that EC8 express Gplb-related mol- 
ecules  responsible  for  ristocetin-dependent  vWF  binding. 
However, Gplb mRNA has not been detected in these cells. 
From the data obtained here we feel confident to rule out a 
significant role for GpIb in EC adhesion to vWF.  Indeed, 
152B-20 fully inhibits EC adhesion to this protein. This pro- 
vides experimental evidence that the RGD containing region 
of vWF which does not bind to Gplb in platelets is most like- 
ly the only binding site of vWF essential for EC adhesion. 
In conclusion,  in this article we report on the ability of 
vWF to act as a matrix protein for ECs supporting adhesion 
and cytoskeletal  organization in these cells.  This strongly 
suggests that vWF,  beside playing a pivotal role in platelet 
adhesion and in maintaining normal hemostasis, significant- 
ly contributes to keeping the anatomical integrity of the inter- 
nal vessel lining. 
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